Innate Pharma SA

NASDAQ:IPHAUnited States

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Contact Information

Headquarters

117 avenue de Luminy, Bp 30191MARSEILLE, France 13009

Phone

---

Fax

---

Executives

Chief Executive Officer, Chairman of the Executive Board

Jonathan Dickinson

Independent Chairwoman of the Supervisory Board

Irina Staatz-Granzer

Chief Financial Officer, Member of the Executive Committee

Frederic Lombard

Chief Operating Officer, Executive Vice President, Member of the Executive Board

Yannis Morel

Executive Vice President, Chief Medical Officer, Member of the Executive Committee

Sonia Quaratino